DCC-2036
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
TPS2666 Background: Rebastinib is a potent, orally administered, kinase switch control inhibitor selectively targeting the tunica…
The paradigm-shifting clinical success of imatinib in the treatment of chronic myeloid leukemia (CML) established continuous…
In some types of tumors, malignant cells are highly dependent on the constitutive activation of a certain protein encoded by…
Th e introduction in clinical practice of tyrosine kinase inhibitors (TKIs) targeting the oncogenic BCR – ABL protein has had a…
The 21st century ushered in the dawn of a new era of targeted therapeutics and a dramatic shift in the management of chronic…
Abstract 601 Background. DCC-2036 is a novel and potent tyrosine kinase inhibitor (TKI) which binds to a novel region called the…
Abstract 3398 Chronic Myeloid Leukemia (CML) treatment was radically modified by the discovery of imatinib (IM), a selective…
Abstract 1226 Background: Mutations in the kinase domain (KD) of Abl represent the most common mechanism of resistance to…
Therapy with ATP-competitive ABL kinase inhibitors, including imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna…